{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:37Z","timestamp":1792839637989,"version":"4.5.0"},"reference-count":180,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50GM115305"],"award-info":[{"award-number":["P50GM115305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jaci.2015.05.050","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T13:11:39Z","timestamp":1438866699000},"page":"219-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Evolving models of the immunopathogenesis of T\u00a0cell\u2013mediated drug allergy: The role of host, pathogens, and drug response"],"prefix":"10.1016","volume":"136","author":[{"given":"Katie D.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2015.05.050_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2015.05.050_bib2","doi-asserted-by":"crossref","first-page":"e33236","DOI":"10.1371\/journal.pone.0033236","article-title":"Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions\u2014a meta-analysis","volume":"7","author":"Hakkarainen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.050_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospectivhe observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaci.2015.05.050_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1345\/aph.10094","article-title":"Clinical and economic impact of adverse drug reactions in hospitalized patients","volume":"34","author":"Suh","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaci.2015.05.050_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2015.05.050_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2015.05.050_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2015.05.050_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib9","series-title":"Textbook of adverse drug reactions","first-page":"10","article-title":"Pathogenesis of adverse drug reactions","author":"Rawlins","year":"1977"},{"key":"10.1016\/j.jaci.2015.05.050_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.050_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2015.05.050_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev-med-050913-022745","article-title":"T cell-mediated hypersensitivity reactions to drugs","volume":"66","author":"Pavlos","year":"2015","journal-title":"Annu Rev Medicine"},{"key":"10.1016\/j.jaci.2015.05.050_bib13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.050_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.050_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2015.05.050_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1533-2500.2011.00479.x","article-title":"HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain","volume":"12","author":"Kulkantrakorn","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.jaci.2015.05.050_bib19","first-page":"290","article-title":"Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients","volume":"29","author":"Then","year":"2011","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaci.2015.05.050_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.jaci.2015.05.050_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.050_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaci.2015.05.050_bib24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaci.2015.05.050_bib25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","article-title":"HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population","volume":"39","author":"Niihara","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jaci.2015.05.050_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaci.2015.05.050_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2015.05.050_bib31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaci.2015.05.050_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib34","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2015.05.050_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jaci.2015.05.050_bib38","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaci.2015.05.050_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaci.2015.05.050_bib41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000248097","article-title":"HLA and allopurinol drug eruption","volume":"179","author":"Chan","year":"1989","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaci.2015.05.050_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe","volume":"6","author":"Genin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1607-551X(09)70045-2","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a case report","volume":"25","author":"Lin","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jaci.2015.05.050_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eplepsyres.2010.10.006","article-title":"Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population","volume":"92","author":"An","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaci.2015.05.050_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1742-7843.2011.00681.x","article-title":"Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population","volume":"109","author":"Shi","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaci.2015.05.050_bib49","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1089\/aid.2011.0107","article-title":"HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients","volume":"28","author":"Gao","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jaci.2015.05.050_bib54","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/QAD.0000000000000345","article-title":"HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity","volume":"28","author":"Keane","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/cir403","article-title":"Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash","volume":"53","author":"Chantarangsu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib59","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate\u2013induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2015.05.050_bib61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","article-title":"Co-amoxiclav jaundice: clinical and histological features and HLA class II association","volume":"47","author":"O'Donohue","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2015.05.050_bib62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2015.05.050_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaci.2015.05.050_bib65","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1240009","article-title":"Genetic association studies in drug-induced liver injury","volume":"29","author":"Daly","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03602532.2011.605790","article-title":"Genetic association studies in drug-induced liver injury","volume":"44","author":"Daly","year":"2012","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jaci.2015.05.050_bib67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2015.05.050_bib68","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2015.05.050_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaci.2014.07.047","article-title":"HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping","volume":"135","author":"Gueant","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib71","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2015.05.050_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib73","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1126\/science.1058867","article-title":"Preferential localization of effector memory cells in nonlymphoid tissue","volume":"291","author":"Masopust","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jaci.2015.05.050_bib74","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2012.09.020","article-title":"Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets","volume":"38","author":"Sathaliyawala","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.050_bib75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.20061792","article-title":"Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation","volume":"204","author":"Zhu","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib76","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.141.10.3249","article-title":"Differential activation requirements for virgin and memory T cells","volume":"141","author":"Byrne","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib77","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.V86.4.1408.bloodjournal8641408","article-title":"Direct demonstration of cytokine synthesis heterogeneity among human memory\/effector T cells by flow cytometry","volume":"86","author":"Picker","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2015.05.050_bib78","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/eji.1830190504","article-title":"Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation","volume":"19","author":"Sanders","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib79","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.4049\/jimmunol.160.7.3236","article-title":"CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR\/CD8 signaling in response to antigen","volume":"160","author":"Curtsinger","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib81","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cub.2005.04.050","article-title":"Pathogen-driven selection and worldwide HLA class I diversity","volume":"15","author":"Prugnolle","year":"2005","journal-title":"Curr Biol"},{"key":"10.1016\/j.jaci.2015.05.050_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00251-011-0576-y","article-title":"Signatures of historical demography and pathogen richness on MHC class I genes","volume":"64","author":"Qutob","year":"2012","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jaci.2015.05.050_bib83","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrg1489","article-title":"Gene map of the extended human MHC","volume":"5","author":"Horton","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib85","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/hep.21889","article-title":"Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection","volume":"46","author":"Hraber","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jaci.2015.05.050_bib86","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1126\/science.283.5408.1748","article-title":"HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage","volume":"283","author":"Carrington","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jaci.2015.05.050_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ng0997-11","article-title":"Heterozygote advantage for HLA class-II type in hepatitis B virus infection","volume":"17","author":"Thursz","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2015.05.050_bib88","series-title":"Handbook of pharmacogenomics and stratified medicine","first-page":"437","article-title":"HLA and the pharmacogenomics of drug hypersensitivity","author":"White","year":"2014"},{"key":"10.1016\/j.jaci.2015.05.050_bib89","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1034\/j.1398-9995.2002.02161.x","article-title":"Pathogenesis of drug-induced exanthems","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.05.050_bib90","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0300-483X(00)00397-8","article-title":"Metabolic activation in drug allergies","volume":"158","author":"Park","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.jaci.2015.05.050_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bjp.0704074","article-title":"Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in\u00a0vivo","volume":"133","author":"Naisbitt","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.050_bib93","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/eji.1830260107","article-title":"T cell recognition of penicillin G: structural features determining antigenic specificity","volume":"26","author":"Padovan","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2332\/allergolint.55.17","article-title":"Pharmacological interaction of drugs with immune receptors: the p-i concept","volume":"55","author":"Pichler","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2015.05.050_bib95","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI3544","article-title":"HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes","volume":"102","author":"Zanni","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2015.05.050_bib96","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/intimm\/10.4.507","article-title":"Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta+ T cell clones","volume":"10","author":"Zanni","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib97","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI119505","article-title":"Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones","volume":"100","author":"Schnyder","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2015.05.050_bib98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1573395510666140407212357","article-title":"Interaction of small molecules with specific immune receptors: the p-i concept and its consequences","volume":"10","author":"Pichler","year":"2014","journal-title":"Curr Immunol Rev"},{"key":"10.1016\/j.jaci.2015.05.050_bib99","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaci.2015.05.050_bib100","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib101","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","article-title":"Abacavir induces loading of novel self-peptides into HLA-B*57:01: an autoimmune model for HLA-associated drug hypersensitivity","volume":"26","author":"Norcross","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib102","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2015.05.050_bib103","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2015.05.050_bib104","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1345\/aph.1E202","article-title":"Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir","volume":"38","author":"Cutrell","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaci.2015.05.050_bib105","first-page":"222","article-title":"A near-fatal hypersensitivity reaction to abacavir: case report and literature review","volume":"11","author":"Shapiro","year":"2001","journal-title":"AIDS Read"},{"key":"10.1016\/j.jaci.2015.05.050_bib106","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/00002030-200211080-00017","article-title":"Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir","volume":"16","author":"Phillips","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib107","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/135965350801300814","article-title":"Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study","volume":"13","author":"Rauch","year":"2008","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study","volume":"43","author":"Rauch","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib109","doi-asserted-by":"crossref","first-page":"e0117160","DOI":"10.1371\/journal.pone.0117160","article-title":"Abacavir-reactive memory T cells are present in drug naive individuals","volume":"10","author":"Lucas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.050_bib110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2015.05.050_bib111","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/eji.201142159","article-title":"Avidity determines T-cell reactivity in abacavir hypersensitivity","volume":"42","author":"Adam","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib112","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.050_bib113","doi-asserted-by":"crossref","first-page":"e95339","DOI":"10.1371\/journal.pone.0095339","article-title":"Abacavir induced T cell reactivity from drug naive individuals shares features of allo-immune responses","volume":"9","author":"Adam","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.050_bib114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","article-title":"Anticonvulsant hypersensitivity syndrome: incidence, prevention and management","volume":"21","author":"Knowles","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.jaci.2015.05.050_bib115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Ind J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaci.2015.05.050_bib116","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","article-title":"HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review","volume":"92","author":"Yip","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib117","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib118","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib119","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1346-8138.2011.01421.x","article-title":"Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101","volume":"39","author":"Mizumoto","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/FPC.0000000000000021","article-title":"HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis","volume":"24","author":"Grover","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib121","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib122","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.050_bib123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00228-004-0753-0","article-title":"Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions","volume":"60","author":"Lee","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.050_bib124","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/jac\/dku315","article-title":"CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations","volume":"69","author":"Carr","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaci.2015.05.050_bib125","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1128\/AAC.02069-13","article-title":"Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi","volume":"58","author":"Dickinson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2015.05.050_bib126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","article-title":"Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?","volume":"215","author":"Dainichi","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2015.05.050_bib127","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib128","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaci.2015.05.050_bib129","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2015.05.050_bib130","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib131","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jaci.2014.09.041","article-title":"Immunologic basis for allopurinol-induced severe cutaneous reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction","volume":"135","author":"Lin","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib132","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib133","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib134","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.0105-2896.2010.00897.x","article-title":"Heterologous immunity between viruses","volume":"235","author":"Welsh","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2015.05.050_bib135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1292","article-title":"The many important facets of T-cell repertoire diversity","volume":"4","author":"Nikolich-Zugich","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0167-5699(98)01299-7","article-title":"A very high level of crossreactivity is an essential feature of the T-cell receptor","volume":"19","author":"Mason","year":"1998","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2015.05.050_bib137","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri820","article-title":"No one is naive: the significance of heterologous T-cell immunity","volume":"2","author":"Welsh","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib138","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood-2009-07-234906","article-title":"Allo-HLA reactivity of virus-specific memory T cells is common","volume":"115","author":"Amir","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2015.05.050_bib139","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-5699(98)01429-7","article-title":"The influence of antiviral T-cell responses on the alloreactive repertoire","volume":"20","author":"Burrows","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2015.05.050_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.tp.0000226082.17507.da","article-title":"The impact of memory T cells on rejection and the induction of tolerance","volume":"82","author":"Brook","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2015.05.050_bib141","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.trim.2010.06.008","article-title":"Alloreactivity from human viral specific memory T-cells","volume":"23","author":"D'Orsogna","year":"2010","journal-title":"Transplant Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib142","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.humimm.2004.02.014","article-title":"CD8(+) T-cell immunity to cytomegalovirus","volume":"65","author":"Moss","year":"2004","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib143","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1128\/JVI.76.8.3748-3755.2002","article-title":"Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus","volume":"76","author":"Sester","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jaci.2015.05.050_bib144","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1006\/viro.2000.0697","article-title":"Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects","volume":"279","author":"Komanduri","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.jaci.2015.05.050_bib145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib146","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib147","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.immuni.2009.09.025","article-title":"T cell allorecognition via molecular mimicry","volume":"31","author":"Macdonald","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.050_bib148","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.immuni.2009.12.002","article-title":"The multiple mechanisms of T cell receptor cross-reactivity","volume":"31","author":"Yin","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.050_bib149","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni891","article-title":"CDR3 loop flexibility contributes to the degeneracy of TCR recognition","volume":"4","author":"Reiser","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1074-7613(02)00288-1","article-title":"A T cell receptor CDR3beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide\/MHC class I complex","volume":"16","author":"Reiser","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.050_bib151","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2007.01.048","article-title":"How a single T cell receptor recognizes both self and foreign MHC","volume":"129","author":"Colf","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2015.05.050_bib152","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2013.04.013","article-title":"HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity","volume":"132","author":"Schnyder","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib153","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2015.05.050_bib154","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","article-title":"A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions","volume":"27","author":"Lin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2015.05.050_bib155","unstructured":"Lin Y.T. Patch test in carbamazepine induced Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN). Presented at: 8th International Congress on Cutaneous Adverse Drug Reactions (iSCAR); 2013; Taoyuan, Taiwan."},{"key":"10.1016\/j.jaci.2015.05.050_bib156","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","article-title":"Redefining chronic viral infection","volume":"138","author":"Virgin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2015.05.050_bib157","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature12110","article-title":"Immune surveillance by CD8alphaalpha+ skin-resident T cells in human herpes virus infection","volume":"497","author":"Zhu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2015.05.050_bib158","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2015.05.050_bib160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib161","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","article-title":"Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome","volume":"157","author":"Tohyama","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib162","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2133.2006.07332.x","article-title":"Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome","volume":"155","author":"Seishima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2015.05.050_bib163","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib164","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.autrev.2009.02.029","article-title":"Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes","volume":"8","author":"Aota","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2015.05.050_bib165","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib166","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5694\/mja12.10477","article-title":"Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele","volume":"197","author":"Harding","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaci.2015.05.050_bib167","doi-asserted-by":"crossref","first-page":"867389","DOI":"10.1155\/2013\/867389","article-title":"Possible role of human herpesvirus 6 as a trigger of autoimmune disease","volume":"2013","author":"Broccolo","year":"2013","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.jaci.2015.05.050_bib168","doi-asserted-by":"crossref","first-page":"e1002951","DOI":"10.1371\/journal.ppat.1002951","article-title":"Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis","volume":"8","author":"Caselli","year":"2012","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.jaci.2015.05.050_bib169","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/TP.0b013e318207944c","article-title":"Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells","volume":"91","author":"D'Orsogna","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2015.05.050_bib170","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/intimm\/13.7.877","article-title":"Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones","volume":"13","author":"von Greyerz","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2015.05.050_bib171","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing","volume":"91","author":"Martin","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib172","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.jaci.2015.05.050_bib173","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/605292","article-title":"Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America","volume":"49","author":"Aberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2015.05.050_bib174","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/pgs.10.147","article-title":"Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics","volume":"12","author":"Becquemont","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib175","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2014an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib176","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaci.2015.05.050_bib177","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib178","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.050_bib179","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience","volume":"15","author":"Goldkind","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaci.2015.05.050_bib180","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0009-9236(98)90093-5","article-title":"Serum sickness-like reaction to cefaclor: lack of in\u00a0vitro cross-reactivity with loracarbef","volume":"63","author":"Kearns","year":"1998","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915008696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915008696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:52:10Z","timestamp":1758790330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674915008696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":180,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0091674915008696"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2015.05.050","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving models of the immunopathogenesis of T\u00a0cell\u2013mediated drug allergy: The role of host, pathogens, and drug response","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2015.05.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}